Healthcare Industry News: Bristol-Myers Squibb
News Release - March 18, 2008
Worldwide Leader in Diagnostic Medicine is Launched as Lantheus Medical ImagingCompany Also Announces Senior Management Team
N. BILLERICA, Mass.--(HSMN NewsFeed)--A worldwide leader and pioneer in medical imaging announces a new name—Lantheus Medical Imaging—and management team. In business for more than half a century, the company, most recently known as Bristol-Myers Squibb Medical Imaging, provides innovative medical imaging products for nuclear and ultrasound cardiovascular diagnostic imaging procedures, including Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension and TechneLite® (Technetium Tc99m Generator). The launch builds on the momentum created by the acquisition of the business by Avista Capital Partners in January of this year.
“Lantheus Medical Imaging’s heritage and strong position in the field of diagnostic medicine provides a solid foundation on which to build a dynamic and vibrant company focused on meeting the needs of customers and patients,” said Larry Pickering, Executive Chairman, Lantheus Medical Imaging, and Avista Capital Partners’ healthcare industry partner. “I am impressed by the strong team our recently appointed President and CEO Don Kiepert has assembled to lead Lantheus Medical Imaging and have tremendous confidence in their ability to maximize the company’s potential as it enters the next phase of its evolution.”
Don Kiepert, President and CEO, Lantheus Medical Imaging added, “Lantheus Medical Imaging is well-positioned for growth with a market-leading product portfolio, promising pipeline, and a world-class organization committed to the field of medical imaging. Our people are passionate about developing innovative, clinically meaningful diagnostic tools that enhance and improve patient care.”
Before joining Lantheus Medical Imaging, Mr. Kiepert was the founder and former Chairman, CEO and President of Point Therapeutics since 1996. Prior to that he was President and Chief Executive Officer of Chartwell Home Therapies, a home infusion services company, from 1989 to 1996. Mr. Kiepert also started and managed several health care companies and worked in various management positions at Baxter Travenol, Inc. Mr. Kiepert received his M.S. degree in clinical pharmacy from Purdue University.
In conjunction with the launch of the business, Lantheus Medical Imaging has also announced key members of its management team. New appointments to the management team include: Phillip Lockwood, Vice President, Human Resources, formerly Vice President, Human Resources at Indevus Pharmaceuticals, and Michael Duffy, Vice President and General Counsel, formerly Senior Vice President and General Counsel at Point Therapeutics. In addition, David Mann, formerly Vice President, Sales, was promoted to Vice President, Sales and Marketing. Additional members of the management team include: Peter Card, Vice President, Strategy and Business Development; William Dawes, Vice President, Manufacturing and Supply Chain; Scott Edwards, Vice President, Global R&D Robert Gaffey, Vice President, Finance and Operations; and Cyrille Villeneuve, General Manager Canada, Latin America, Pacific Rim.
Lantheus Medical Imaging’s rich heritage is captured in the company’s new brand identity. In “Lantheus” the company has a name that communicates illumination, innovation and leadership—hallmarks of the company’s heritage that will characterize the organization’s future.
About Lantheus Medical Imaging
Lantheus Medical Imaging is a worldwide leader in medical imaging, with headquarters in North Billerica, Massachusetts, and nearly 700 employees worldwide with offices in Puerto Rico, Canada, and Australia. For more than half a century, the company has provided important products—including Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension and TechneLite® (Technetium Tc99m Generator)—that illuminate the heart and other organs. Lantheus Medical Imaging will build on the solid foundation created by those products as it seeks out new ways of “bringing light” to the diagnosis and management of disease. For more information, visit www.lantheus.com.
Source: Lantheus Medical Imaging
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.